ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Back to dashboard
Company Information
About this company
Key people
Eugene Jiang
Chairman of the Board, Chief Business Officer
Uttam Yashwant Patil
Chief Executive Officer, Interim Chief Financial Officer
Tsung-Shann Jiang
Chief Scientific Officer, Chief Strategy Officer, Director
Chang-Jen Jiang
Director
Shuling Jiang
Director
Tsang Ming Jiang
Director
Yen-Hsin Chou
Independent Director
Yu- Min Chung
Independent Director
Click to see more
Key facts
- Shares in issue27.43m
- EPICABVC
- ISINUS00091F3047
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$24.50m
- Employees19
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.